@article{eeb85ac726ec4adb96b3af9d22a987f6,
title = "Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024",
author = "{de Bono}, Johann and Maha Hussain and Jinyu Kang",
note = "Funding Information: Conflicts of interest: Johann de Bono has received consulting fees and advisory board fees from Astellas Pharma, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen Global Services, Menarini Silicon Biosystems, Merck, Merck Sharp & Dohme, Orion, Pfizer, Qiagen Sciences, Sanofi-Aventis U.S., Sierra Oncology, Taiho Pharmaceutical, and Vertex Pharmaceuticals; holds interest in a patent (WO/2005/053662) on DNA damage repair inhibitors for treatment of cancer, held by the Institute of Cancer Research and licensed to AstraZeneca, and a patent (US5604213) on 17-substituted steroids useful in cancer treatment, held by the Institute of Cancer Research and licensed to Janssen Global Services. Maha Hussain has received lecture fees and travel support from Astellas Pharma; institutional grant support from AstraZeneca, Bayer, Genentech, and Pfizer; advisory board fees from Bayer, Daiichi Sankyo, and Genentech; and lecture fees from Sanofi and Genzyme. Jinyu Kang is employed by and owns stock in AstraZeneca. The study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing assistance was provided by Martin Goulding of Mudskipper Business, funded by AstraZeneca and Merck Sharp & Dohme Corp. Funding Information: Conflicts of interest: Johann de Bono has received consulting fees and advisory board fees from Astellas Pharma , AstraZeneca , Bayer HealthCare , Boehringer Ingelheim , Daiichi Sankyo , Genentech , GlaxoSmithKline , Janssen Global Services , Menarini Silicon Biosystems , Merck , Merck Sharp & Dohme , Orion , Pfizer , Qiagen Sciences , Sanofi-Aventis U.S. , Sierra Oncology , Taiho Pharmaceutical , and Vertex Pharmaceuticals ; holds interest in a patent (WO/2005/053662) on DNA damage repair inhibitors for treatment of cancer, held by the Institute of Cancer Research and licensed to AstraZeneca, and a patent (US5604213) on 17-substituted steroids useful in cancer treatment, held by the Institute of Cancer Research and licensed to Janssen Global Services. Maha Hussain has received lecture fees and travel support from Astellas Pharma; institutional grant support from AstraZeneca, Bayer, Genentech, and Pfizer; advisory board fees from Bayer, Daiichi Sankyo, and Genentech; and lecture fees from Sanofi and Genzyme. Jinyu Kang is employed by and owns stock in AstraZeneca. The study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing assistance was provided by Martin Goulding of Mudskipper Business, funded by AstraZeneca and Merck Sharp & Dohme Corp.",
year = "2021",
month = mar,
doi = "10.1016/j.eururo.2020.12.016",
language = "English (US)",
volume = "79",
pages = "e83--e84",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",
}
